Is Mind Medicine Stock a Good Investment?
Mind Medicine Investment Advice | MNMD |
- Examine Mind Medicine's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Mind Medicine's leadership team and their track record. Good management can help Mind Medicine navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Mind Medicine's business and its evolving consumer preferences.
- Compare Mind Medicine's performance and market position to its competitors. Analyze how Mind Medicine is positioned in terms of product offerings, innovation, and market share.
- Check if Mind Medicine pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Mind Medicine's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Mind Medicine stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Mind Medicine is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Mind Medicine Stock
Researching Mind Medicine's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 57.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.88. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Mind Medicine recorded a loss per share of 1.71. The entity last dividend was issued on the 27th of February 2020. The firm had 1:15 split on the 29th of August 2022.
To determine if Mind Medicine is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Mind Medicine's research are outlined below:
| Mind Medicine generated a negative expected return over the last 90 days | |
| Mind Medicine has high historical volatility and very poor performance | |
| Net Loss for the year was (95.73 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Mind Medicine currently holds about 105.74 M in cash with (64.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.71. | |
| Mind Medicine has a frail financial position based on the latest SEC disclosures | |
| Roughly 57.0% of the company shares are owned by institutional investors | |
| Latest headline from businesswire.com: MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 |
Mind Medicine Quarterly Accounts Payable |
|
Mind Medicine uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Mind Medicine. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Mind Medicine's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Mind Medicine's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Mind Medicine's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-13 | 2024-06-30 | -0.33 | -0.26 | 0.07 | 21 | ||
2023-05-04 | 2023-03-31 | -0.42 | -0.52 | -0.1 | 23 | ||
2024-02-28 | 2023-12-31 | -0.46 | -0.59 | -0.13 | 28 | ||
2022-08-11 | 2022-06-30 | -0.75 | -0.6 | 0.15 | 20 | ||
2022-05-16 | 2022-03-31 | -0.75 | -0.6 | 0.15 | 20 | ||
2021-03-30 | 2020-12-31 | -0.3 | -0.15 | 0.15 | 50 | ||
2021-05-14 | 2021-03-31 | -0.23 | -0.04 | 0.19 | 82 | ||
2023-11-02 | 2023-09-30 | -0.67 | -0.45 | 0.22 | 32 |
Mind Medicine Target Price Consensus
Mind target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Mind Medicine's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 4 | Strong Buy |
Most Mind analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Mind stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Mind Medicine, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationMind Medicine Target Price Projection
Mind Medicine's current and average target prices are 6.70 and 8.00, respectively. The current price of Mind Medicine is the price at which Mind Medicine is currently trading. On the other hand, Mind Medicine's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Mind Medicine Target Price
Mind Medicine Analyst Ratings
Mind Medicine's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Mind Medicine stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Mind Medicine's financials, market performance, and future outlook by experienced professionals. Mind Medicine's historical ratings below, therefore, can serve as a valuable tool for investors.Know Mind Medicine's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Mind Medicine is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mind Medicine backward and forwards among themselves. Mind Medicine's institutional investor refers to the entity that pools money to purchase Mind Medicine's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Woodline Partners Lp | 2024-12-31 | 1 M | Tri Locum Partners Lp | 2024-12-31 | 820.8 K | Northern Trust Corp | 2024-12-31 | 684.8 K | Charles Schwab Investment Management Inc | 2024-12-31 | 593.4 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 496.7 K | Ally Bridge Group (ny) Llc | 2024-12-31 | 330.3 K | Goldman Sachs Group Inc | 2024-12-31 | 296.8 K | Nuveen Asset Management, Llc | 2024-09-30 | 277.5 K | Bank Of America Corp | 272.9 K | Blackrock Inc | 2024-12-31 | 6.1 M | Commodore Capital Lp | 2024-12-31 | 4.3 M |
Mind Medicine's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 492.79 M.Market Cap |
|
Mind Medicine's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.06) | (1.11) | |
| Return On Capital Employed | (1.17) | (1.11) | |
| Return On Assets | (0.88) | (0.93) | |
| Return On Equity | (1.41) | (1.34) |
Determining Mind Medicine's profitability involves analyzing its financial statements and using various financial metrics to determine if Mind Medicine is a good buy. For example, gross profit margin measures Mind Medicine's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Mind Medicine's profitability and make more informed investment decisions.
Please note, the presentation of Mind Medicine's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Mind Medicine's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Mind Medicine's management manipulating its earnings.
Evaluate Mind Medicine's management efficiency
Mind Medicine has return on total asset (ROA) of (0.2538) % which means that it has lost $0.2538 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5461) %, meaning that it created substantial loss on money invested by shareholders. Mind Medicine's management efficiency ratios could be used to measure how well Mind Medicine manages its routine affairs as well as how well it operates its assets and liabilities. As of March 1, 2025, Return On Tangible Assets is expected to decline to -1.11. The current year's Return On Capital Employed is expected to grow to -1.11. At present, Mind Medicine's Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Tangible Asset Value is expected to grow to about 3.3 M, whereas Net Tangible Assets are forecasted to decline to about 91.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.29 | 2.18 | |
| Net Current Asset Value | 171.4 K | 147.7 K | |
| Tangible Asset Value | 3.2 M | 3.3 M | |
| Tangible Book Value Per Share | 1.69 | 1.61 | |
| Enterprise Value Over EBITDA | (0.72) | (0.75) | |
| Price Book Value Ratio | 1.65 | 1.82 | |
| Enterprise Value Multiple | (0.72) | (0.75) | |
| Price Fair Value | 1.65 | 1.82 | |
| Enterprise Value | 52 M | 47.9 M |
Mind Medicine has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Beta 2.403 |
Basic technical analysis of Mind Stock
As of the 1st of March, Mind Medicine secures the Standard Deviation of 5.71, mean deviation of 4.39, and Risk Adjusted Performance of 0.0068. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Mind Medicine, as well as the relationship between them. Please verify Mind Medicine information ratio and potential upside to decide if Mind Medicine is priced some-what accurately, providing market reflects its recent price of 6.7 per share. Given that Mind Medicine has information ratio of (0.0004), we recommend you to check Mind Medicine's last-minute market performance to make sure the company can sustain itself at a future point.Mind Medicine's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mind Medicine insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mind Medicine's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Mind Medicine insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mind Medicine's Outstanding Corporate Bonds
Mind Medicine issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Mind Medicine uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Mind bonds can be classified according to their maturity, which is the date when Mind Medicine has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Understand Mind Medicine's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Mind Medicine's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0068 | |||
| Market Risk Adjusted Performance | (0.02) | |||
| Mean Deviation | 4.39 | |||
| Coefficient Of Variation | (37,981) | |||
| Standard Deviation | 5.71 | |||
| Variance | 32.58 | |||
| Information Ratio | (0.0004) | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | 0.1531 | |||
| Treynor Ratio | (0.03) | |||
| Maximum Drawdown | 28.29 | |||
| Value At Risk | (7.99) | |||
| Potential Upside | 9.98 | |||
| Skewness | 0.2386 | |||
| Kurtosis | 0.4486 |
| Risk Adjusted Performance | 0.0068 | |||
| Market Risk Adjusted Performance | (0.02) | |||
| Mean Deviation | 4.39 | |||
| Coefficient Of Variation | (37,981) | |||
| Standard Deviation | 5.71 | |||
| Variance | 32.58 | |||
| Information Ratio | (0.0004) | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | 0.1531 | |||
| Treynor Ratio | (0.03) | |||
| Maximum Drawdown | 28.29 | |||
| Value At Risk | (7.99) | |||
| Potential Upside | 9.98 | |||
| Skewness | 0.2386 | |||
| Kurtosis | 0.4486 |
Consider Mind Medicine's intraday indicators
Mind Medicine intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Mind Medicine stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Mind Medicine Corporate Filings
| 5th of February 2025 Other Reports | ViewVerify | |
8K | 30th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 27th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Mind Stock media impact
Far too much social signal, news, headlines, and media speculation about Mind Medicine that are available to investors today. That information is available publicly through Mind media outlets and privately through word of mouth or via Mind internal channels. However, regardless of the origin, that massive amount of Mind data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Mind Medicine news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Mind Medicine relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Mind Medicine's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Mind Medicine alpha.
Mind Medicine Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Mind Medicine can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Mind Medicine Corporate Management
| MD MA | Chief Officer | Profile | |
| Schond MBA | Chief Officer | Profile | |
| Maxim CFA | Vice Communications | Profile | |
| Wong JD | Chief Sec | Profile | |
| Gregg Pratt | Chief Officer | Profile | |
| MD MBA | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mind Medicine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Mind Stock refer to our How to Trade Mind Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mind Medicine. If investors know Mind will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mind Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mind Medicine is measured differently than its book value, which is the value of Mind that is recorded on the company's balance sheet. Investors also form their own opinion of Mind Medicine's value that differs from its market value or its book value, called intrinsic value, which is Mind Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mind Medicine's market value can be influenced by many factors that don't directly affect Mind Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Mind Medicine's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Mind Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mind Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.